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Summary 
Minor lymphocyte stimulating (Mls) antigens specifically stimulate T cell responses that are restricted 
to particular T cell receptor (TCR) ~ chain variable domains. The Mls phenotype is genetically 
controlled by an open reading frame (off) located in the 3' long terminal repeat of mouse mammary 
tumor virus (MMTV); however, the mechanism ofaction of the off gene product is unknown. 
Whereas predicted off amino acid sequences show strong overall homology, the 20-30 COOH- 
terminal residues are strikingly polymorphic. This polymorphic region correlates with TCR 
Va specificity. We have generated monoclonal ntibodies to a synthetic peptide ncompassing 
the 19 COOH-terminal amino acid residues of Mtv-7 off, which encodes the Mls-1 ' 
determinant. We show here that these antibodies block Mls responses invitro and can interfere 
specifically with thymic clonal deletion of Mls-P reactive Vt~6 + T cells in neonatal mice. 
Furthermore, the antibodies can inhibit V~6 + T cell responses in vivo to an infectious MMTV 
that shares off sequence homology and TCR specificity with Mtv-7. These results confirm the 
predicted extracellular localization of the off COOH terminus and imply that the off proteins 
of both endogenous and exogenous MMTV interact directly with TCR V~. 
E xpression of minor lymphocyte stimulating (Mls) antigens in mice leads to thymic lonal deletion of Mls-reactive 
T cells. In contrast to conventional antigen recognition where 
both the TCR ce and fl chains contribute, T cells interacting 
with a particular Mls antigen are characterized bythe TCR 
Vfl chain they express on the call surface (1, 2). Thus, to as- 
sure stir-tolerance in mice expressing MIs-P, the majority 
of T cells expressing TCR Vfl6, 7, 8.1, and 9 are deleted 
from the mature CD4 + 8- and CD4-8 + thymocytes a well 
as from peripheral T cells (1-4). Encounter of Mls antigens 
later in life can lead to an initial activation of the reactive 
T ceils followed by induction of unresponsiveness and dele- 
tion (5-9). 
Mls phenotypes are encoded by open reading flames (or 0 
in the 3' LTRs of endogenous mouse mammary tumor 
virus (MMTV) (10-14). Transfection studies howed that ex- 
pression of Mtv-7 off leads to stimulation of TCR Vfl6 § 
T ceils (14). 
Additionally, we have recently described infectious 
MMTV(SW) with properties of Mls-P such as activation 
and deletion of the same subsets of T cells and strong off 
sequence homology (9). 
Amino acid sequence comparisons of MMTV orf mole- 
cules suggest acorrelation between the highly polymorphic 
COOH-terminal 20-30 amino acids and the TCR Vfl 
specificity (10-12). In vitro translation studies uggested that 
off molecules are type II membrane proteins (15-17). Thus, 
the COOH terminus would be accessible tothe TCR. There 
is no experimental evidence, however, that MMTV off mol- 
ecules directly interact with the V~ dement of the TCR. 
Herein we describe the characterization of five mAbs specific 
for an Mn,-7 off Peptide ncompassing the 19 COOH-terminal 
amino acids. These mAbs specifically block anti-Mls-1 are- 
sponses in vitro, rescue V~6 + T cells from donal deletion 
in vivo, and strongly inhibit the Vr + T cell response in- 
duced by MMTV(SW) infection in vitro. These results ug- 
gest that the viral superantigen directly interacts with the 
V~ chain of the TCR. 
Materials and Methods 
Production ofAnti-M~7 orfmAbs. For production ofthe mAbs 
described in this study, 8-wk-old BALB/c mice were immunized 
intraperitoneally with 50/~g of the COOH-terminal Mw-7 orf pep- 
tide KILYNMKYTHGGKVGFDPF (9) coupled to albumin i  CFA 
and boosted 4 wk later in IFA. The mouse having the strongest 
titer in serum, as judged by inhibition of an anti-Mls-l" response, 
was reimmunized intravenously and fusions with the myeloma 
X63Ag8 were performed 3 d later. Five mAbs were selected that 
exhibited strong binding to the peptide used for immunization as 
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determined in solid phase ELISA: 6B9.4 (IgG1), 2E5.6 (IgG1), 4D1.3 a 
(IgG1), 6E1.8 (IgG2b), and 1G12.7 (IgM). 
Inhibition of Mls Response In Vitro Mls-l" LBB cells (5-500 x 
103, irradiated with 103 tad using a cobalt source) were cultured 
with 2 x 104 V06 § T hybridoma (RG17) cells for 24-36 h (18). 
Supernatants were tested at different dilutions for IL-2 production 
using CTLL cells as indicator cells. Different doses of protein 
G-Sepharose (Pharmacia, Uppsala, Sweden) -purified antibodies 
and Mtv-7 off peptide were added from the onset of culture. All 
five anti-Mw-7 mAbs were similarly efficient in inhibiting an anti- 
Mls-l" response in vitro (data not shown). 
Expression of M~ 7 orf in Baculovirus. Mtv-7 orfDNA was ob- 
tained by PCR amplification from DNA of BALB.D2 mice using 
the 5' oligonucleotide GATCGTCGACATGCCGCGCCTGCAG- 
CAGA and the 3' oligonucleotide GTGTCGACCCAAACCAAGT- 
CAGGAAACCACTTG (9). The start codon is underlined. The b 
product was cut with the restriction enzyme SalI and ligated into 
the SalI-digested vector pGem3ZF + (Promega Biotec, Madison, 
WI). The insert was excised using the restriction enzymes BamHI 
and HindlII and ligated in the BgllI-EcoRI-digested vector pCSD92 
(obtained from F. Godeau). After 10-h ligation and blunting the 
ends with Klenow fragment the vector was recircularized by liga- 
tion and transfected together with wild-type baculovirus DNA into 
SF9 cells using standard methods. Colonies containing recombinant 
baculovirus were plaque purified twice. SF9 cells were infected with 
a multiplicity of infection of 5 and analyzed 36 h later. 
FACS| FACS | (Becton Dickinson & Co., Mountain 
View, CA) analysis of infected SF9 cells was performed using an 
amplification system consisting of 6 #g of biotinylated antibody 
6E1.8 followed by PE-streptavidin (Caltag Laboratories Inc., Burlin- 
game, CA), 1.25/~g/ml biotinylated antistreptavidin (Vector Labora- 
tories Inc., Burlingame" CA), and PE-labeled streptavidin (19). Dead 
cells were excluded using forward scatter and side scatter analysis. 
For three-color analysis, thymocytes were stained with FITC- 
conjugated anti-Vo6 (44-22-1; 20) or anti-V08.2 (F23.2; 21) anti- 
bodies, PE-conjugated anti-CD4 (GK1.5; Becton Dickinson & Co.), 
and biotinylated anti-CD8 followed by avidin-tandem (Southern 
Biotechnologies, Birmingham, AL). Two-color analysis of thymo- 
cytes (after CD8 depletion with antibody 3.168.1 and rabbit com- 
plement) (22) or lymph node cells was carried out with FITC- 
conjugated anti-Ve antibodies and PE-conjugated anti-CD4. Dead 
cells were gated out using forward scatter and side scatter analysis 
on a FACScan | flow cytometer. 
Virus Isolation and Purification. Virus was purified from milk 
of BALB/c mice carrying MMTV(SW) as described (9). The virus 
was titered using a sandwich ELISA and independently b injec- = 
tion into the foot pads of BALB/c mice and measuring the lymph 
node Vo6+CD4 + T cell response. Limiting virus doses (~10 r virus 
particles) giving an increase of CD4 § V06 + T cells from 10 to 
25% were used in these experiments. 
Results and Discussion 
Based on the off sequences of Mtv-7 (Mls-1 ~) and the 
related infectious MMTV(SW) (9), mouse anti-off mAbs 
specific for a peptide corresponding to the unique 19 COOH-  
terminal amino acid residues were produced. Five mAbs were 
selected based on their strong binding to the Mtv.7 orf pep- 
tide. As shown for the representative antibody 6E1.8 in Fig. 
1 a, all five mAbs inhibited the in vitro anti-Mls-l" response 
of the Va6 + T cell hybrid RG-17. This inhibition was 
specific since addition of the Mr  7 off IX*pride restored a normal 
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Figure 1. Inhibition of Mls-l= response by anti-Mw-7 orf mAbs. (a) The 
Mls-l*-reactive T cell hybrid (KG17) was cultured with Mls-l*-expressing 
LBB cells (18) in the absence orpresence ofdifferent doses of mouse anti- 
orf mAb 6E1.8. After 36 h of coincubation, IL-2 production was assessed 
in the supematants by measuring proliferation ofIb2-dependent CTLL 
cells. (b) Same as a, except using 10 #g/m1 ofmAb 6E1.8 and graded oses 
of Mtv-7 off peptide. 
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Figure 2. Flow microfluorometric analysis of baculovirus-infected SF9 
cells expressing Mtv-7 off. SF9 cells infected with either wild-type baculovirus 
or recombinant baculovirus were stained with biotinyhted anti-Mw-7 orf 
mAb 6E1.8. The signal was amplified with PE-streptavidin, biotinylated 
anti-streptavidin, andPE-streptavidin as described in Materials and Methods. 
(a) Wild-type baculovirus-infected SF9 cells, (b) Mtv-7 off-~pressing SF9 
cells, and (c) same as b, but in the presence of10 #g of the peptide used 
for immunization. 
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Figure 3. Inhibition of thymic 
clonal deletion by anti-orf mAbs. 
V~6 and Ve8.2 expression was 
measured in CD4+CD8 - tby- 
mocytes 6 or 10 d after birth in 
anti-orf-treated or control mAb- 
treated BALB.D2 (Mls-l~) mice 
or in untreated BALB/c (Mls-1 b) 
mice. All the Ig, G anti-orf mAbs 
gave comparable r sults and are 
pooled in this figure. As control 
IgG1, antibody B8-24-3 (anti-H-2 
K b) (25) was used. 
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Figure 4. Inhibition of anti- 
MMTV(SW) T cell response by 
anti-orf mAbs. Adult (5-8 wk 
old) BALB/c mice were injected 
with 10 ~ purified MMTV(SW) 
virus particles as described (9) into 
the left hind footpad. After 12 h 
and every 12 h thereafter, the mice 
were injected in the same footpad 
r with 50 #g of either isotype- 
- matched control antibody (SJL2- 
o 4) (26) or anti-orf mAb 6E1.8 E 
8 (IgG2b). After 4 d the draining 
+ 
lymph nodes were removed and 
single cell suspensions were ana- 
> 
~- lyzed for Vo6+CD4 + or V~14 + 
CD4 § T cells (27). 
response (Fig. 1 b). Furthermore, since RG-17 cells express 
a second TCR V~ chain (Val, provided by the BW fusion 
partner), the response could be restored in the presence of 
staphylococcal enterotoxin A (SEA), which crosslinks Val 
with MHC class II molecules (data not shown). 
Flow microfluorometric analysis of SF9 cells overexpressing 
the Mtv-7 orf molecule 36 h after infection with recombinant 
baculovirus showed strong and specific staining with all the 
anti-orf mAbs. This staining could be completely blocked 
by addition of the Mtv-7 orf peptide (Fig. 2). The orf mole- 
cule in SF9 insect cells might therefore be expressed atthe 
cell surface confirming in vitro translation studies (15-17). 
Similar analysis of Mls-l' LPS induced B cell blasts showed 
very weak to undetectable staining (data not shown). Immu- 
noprecipitation fMtv-7 off molecules from 3SS-methionine- 
labeled infected SF9 cells gave a very similar band pattern 
after SDS-PAGE to that observed by Brandt-Carlson a d Butel 
(23). SF9 cells infected with recombinant baculovirus ex- 
pressing the control orf molecule of MMTV (GK) did not 
yield any detectable bands (data not shown), consistent with 
the fact that MMTV(GR) orf has a completely different 
COOH-terminal sequence. 
In vivo, most Mls-l' mouse strains intrathymicaUy delete 
Mls-P-reactive mature Va6 + T cells within the first 10 d 
after birth (24). This deletion occurs at the transition from 
CD4+8 + to either CD4+8 - or CD4-8 + mature thymo- 
cytes (1). To see whether anti-orf mAbs are able to rescue 
Va6 + T cells from deletion, we injected neonatal Mls-1 ~ 
mice with the different anti-Mtv-7 orf peptide-specific mAbs. 
As shown in Fig. 3, all four IgG antibodies tested were able 
to rescue aconsiderable proportion (40-60%) ofVa6 + ma- 
ture thymocytes from clonal deletion after either two in- 
traperitoneal injections of 70-320 #g of antibody on days 
0 and 4 or after nine daily injections with 100 #g starting 
within the first 24 h after birth. The percentage ofT cells 
expressing TCR molecules not interacting with Mls-1 ~ 
(VaS.2, Va14) did not change, and isotype-matched control 
antibody did not interfere with the clonal deletion patterns 
(Fig. 3). 
We recently described the characterization f infectious 
MMTV(SW) that has the same TCR specificity as Mls-1 ~ 
(Mtv-7 off) and displays avery similar COOH-terminal orf 
amino acid sequence (9). Thus, we attempted using the anti- 
off mAbs to interfere with a proliferative Va6 + CD4 + re- 
sponse induced after MMTV(SW) infection in vivo. Prelim- 
inary experiments determined the minimal virus dose (~107 
particles) required for a significant and specific (2.5-fold) in- 
crease in Va6 +CD4 + T cells in the draining lymph nodes. 
We injected 50 #g of anti-orf mAb 6E1.8 (IgG2b) 12 h after 
virus challenge into the hind footpad and repeated the anti- 
body injections every 12 h until day 4, when the lymph node 
cells were isolated. As can be seen in Fig. 4, a strong and 
specific inhibition of the local increase of Va6 + CD4 + T cells 
is observed in anti-off-treated but not control IgG2b-treated 
mice. This effect likely represents blocking of orf presenta- 
tion to V~ + T cells by MMTV(SW)-infected B cells, since 
the antibody should not interfere with MMTV infection per se. 
In conclusion, the results described here indicate that 
MMTV orf molecules are expressed on the cell surface and 
that the off COOH terminus i accessible toantibodies, thus 
confirming predictions made from sequence omparisons and 
in vitro translation studies. Furthermore, the in vivo blocking 
data indicate that MMTV-induced T cell stimulation and de- 
letion both depend upon direct interaction of TCR Va with 
the off protein. 
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